- Home
- BYSI vs TCRX Comparison
BYSI vs TCRX Comparison
Compare BYSI & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYSI | TCRX |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.0M | 64.1M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BYSI | TCRX |
|---|---|---|
| Price | $1.67 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 67.5K | ★ 554.3K |
| Earning Date | 02-11-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,423,000.00 |
| Revenue This Year | N/A | $286.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.98 | $0.88 |
| 52 Week High | $3.44 | $2.67 |
Technical Indicators
Market Signals| Indicator | BYSI | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.14 | 56.62 |
| Support Level | $1.62 | $1.09 |
| Resistance Level | $1.77 | $1.27 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 73.08 | 67.17 |
Price Performance
Historical ComparisonAbout BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.